Sir Richard Peto, professor of medical statistics and epidemiology at the University of Oxford, said cancer increase in SEAS data is "hypothesis-generating," but is not supported by his analysis of data from two ongoing 20,000-patient ezetimibe/simvastatin trials. The FDA has been informed of the findings.Developing story.
More...